Abbvie share price today

(ABBV)

Abbvie share price is $175.58 & ₹14,920.09 as on 21 Dec 2024, 2.30 'hrs' IST

$175.58

▲

4.06

(2.37%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Abbvie share price in Dollar and Rupees. Guide to invest in Abbvie from India. Also see the sentimental analysis on Indian investors investing in Abbvie. Get details on the Indian mutual funds that are investing in Abbvie. Get Analyst recommendations and forecasts along with all the Abbvie's financials.

Abbvie share price movements

Today's Low: $171.58
Today's High: $176.75
$175.58
2.28%
Downside
Day's Volatility :2.93%
Upside
0.66%
52 Weeks Low: $153.09
52 Weeks High: $207.32
$175.58
12.81%
Downside
52 Weeks Volatility :26.16%
Upside
15.31%

Abbvie Returns

Period	Abbvie Inc	Sector (Health Care)	S&P500
3 Months	-9.42%	-11.1%	4.0%
6 Months	1.64%	-6.0%	8.5%
1 Year	13.56%	2.2%	24.7%
3 Years	31.93%	-0.5%	26.3%

Abbvie Key Statistics

in dollars & INR

Previous Close	$171.52
Open	$171.794
Today's High	$176.75
Today's Low	$171.58
Market Capitalization	$303.1B
Today's Volume	$13.3M
52 Week High	$207.32
52 Week Low	$153.0891
Revenue TTM	$55.5B
EBITDA	$25.6B
Earnings Per Share (EPS)	$2.86
PE Ratio	59.97
Dividend Yield	3.82%
Profit Margin	9.22%
Quarterly Earnings Growth YOY	-0.12%
Return On Equity TTM	56.41%

How to invest in Abbvie from India?

It is very easy for Indian residents to invest directly in Abbvie from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Abbvie stock in both Indian Rupees (INR) and US Dollars (USD). Search for Abbvie or ABBV on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Abbvie or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Abbvie shares which would translate to 0.005 fractional shares of Abbvie as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Abbvie, in just a few clicks!

Returns in Abbvie for Indian investors in Rupees

Investment Value

₹1,00,000

Abbvie investment value today

Current value as on today

₹1,15,752

Returns

₹15,752

(+15.75%)

Returns from Abbvie Stock

₹13,556 (+13.56%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Abbvie

-38.11%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Investment in Abbvie from India has reduced in the last 30 days as on Dec 22, 2024. -38.11% less purchase transactions for Abbvie in the last 30 days versus the previous period.

-18%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Abbvie on INDmoney from India has reduced in the last 30 days as on Dec 22, 2024. -18% less investors are searching Abbvie in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Abbvie

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	15179	-1756.21	0.62%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	2474	0.00	2.71%

Global Institutional Holdings in Abbvie

Vanguard Group Inc
9.71%
BlackRock Inc
7.72%
State Street Corp
4.47%
JPMorgan Chase & Co
2.95%
Morgan Stanley - Brokerage Accounts
2.19%
Capital Research & Mgmt Co - Division 3
2.08%

Analyst Recommendation on Abbvie

Buy

65%Buy

34%Hold

0%Sell

Based on 35 Wall street analysts offering stock ratings for Abbvie(by analysts ranked 0 to 5 stars)

Based on 35 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Abbvie

What analysts predicted

Upside of 15.36%

Current:

$175.58

Target:

$202.54

Insights on Abbvie

Price Movement
In the last 7 days, ABBV stock has moved up by 1.3%
Decreasing Revenue
Abbvie Inc has experienced a stable revenue trend over the last two quarters, with revenue remaining constant at $14.46 billion in each quarter. There has been no average decrease in revenue, indicating a consistent performance.
Increasing Net Profit
Abbvie Inc has shown a positive trend in its net profit over the last four quarters. The company’s net profit has increased from $822 million to $1.56 billion, achieving an average growth of 17.4% each quarter.
ABBV vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 34.6% return, outperforming this stock by 21.3%
ABBV vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 188.1% return, outperforming this stock by 155.1%
Price to Sales
Abbvie Inc has a Price-to-Sales Ratio of 5.6, meaning investors are willing to pay $5.6 for every $1 of sales the company generates. In comparison, Eli Lilly And Company has a much higher Price-to-Sales Ratio of 16.9, indicating that investors value their sales more highly than those of Abbvie.

Abbvie Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$32.8B	↑ 16.08%
Net Income	$5.7B	↑ 7.12%
Net Profit Margin	17.36%	↓ 1.46%

	FY19	Y/Y Change
Revenue	$33.3B	↑ 1.57%
Net Income	$7.9B	↑ 38.6%
Net Profit Margin	23.69%	↑ 6.33%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 37.69%
Net Income	$4.6B	↓ 41.44%
Net Profit Margin	10.08%	↓ 13.61%

	FY21	Y/Y Change
Revenue	$56.2B	↑ 22.69%
Net Income	$11.5B	↑ 150.04%
Net Profit Margin	20.54%	↑ 10.46%

	FY22	Y/Y Change
Revenue	$58.1B	↑ 3.3%
Net Income	$11.8B	↑ 2.55%
Net Profit Margin	20.39%	↓ 0.15%

	FY23	Y/Y Change
Revenue	$54.3B	↓ 6.44%
Net Income	$4.9B	↓ 58.91%
Net Profit Margin	8.95%	↓ 11.44%

	Q2 FY23	Q/Q Change
Revenue	$13.9B	↑ 13.42%
Net Income	$2.0B	↑ 746.86%
Net Profit Margin	14.6%	↑ 12.64%

	Q3 FY23	Q/Q Change
Revenue	$13.9B	↑ 0.45%
Net Income	$1.8B	↓ 12.15%
Net Profit Margin	12.77%	↓ 1.83%

	Q4 FY23	Q/Q Change
Revenue	$14.3B	↑ 2.69%
Net Income	$822.0M	↓ 53.77%
Net Profit Margin	5.75%	↓ 7.02%

	Q1 FY24	Q/Q Change
Revenue	$12.3B	↓ 13.92%
Net Income	$1.4B	↑ 66.55%
Net Profit Margin	11.12%	↑ 5.37%

	Q2 FY24	Q/Q Change
Revenue	$14.5B	↑ 17.48%
Net Income	$1.4B	↑ 0.07%
Net Profit Margin	9.47%	↓ 1.65%

	Q3 FY24	Q/Q Change
Revenue	$14.5B	↓ 0.01%
Net Income	$1.6B	↑ 13.94%
Net Profit Margin	10.8%	↑ 1.33%

	FY18	Y/Y Change
Profit	$25.0B	↑ 18.22%

	FY19	Y/Y Change
Profit	$25.8B	↑ 3.16%

	FY20	Y/Y Change
Profit	$30.4B	↑ 17.77%

	FY21	Y/Y Change
Profit	$38.8B	↑ 27.4%

	FY22	Y/Y Change
Profit	$40.6B	↑ 4.87%

	FY23	Y/Y Change
Profit	$33.9B	↓ 16.58%

	Q2 FY23	Q/Q Change
Profit	$9.6B	↑ 16.82%

	Q3 FY23	Q/Q Change
Profit	$7.4B	↓ 22.68%

	Q4 FY23	Q/Q Change
Profit	$11.9B	↑ 60.1%

	Q1 FY24	Q/Q Change
Profit	$8.2B	↓ 30.94%

	Q2 FY24	Q/Q Change
Profit	$12.3B	↑ 49.32%

	Q3 FY24	Q/Q Change
Profit	$10.2B	↓ 16.59%

	FY18	Y/Y Change
Operating Cash Flow	$13.4B	↑ 34.81%
Investing Cash Flow	$-1.0B	↑ 267.15%
Financing Cash Flow	$-14.4B	↑ 161.18%

	FY19	Y/Y Change
Operating Cash Flow	$13.3B	↓ 0.77%
Investing Cash Flow	$596.0M	↓ 159.24%
Financing Cash Flow	$18.7B	↓ 229.95%

	FY20	Y/Y Change
Operating Cash Flow	$17.6B	↑ 32.0%
Investing Cash Flow	$-37.6B	↓ 6401.51%
Financing Cash Flow	$-11.5B	↓ 161.48%

	FY21	Y/Y Change
Operating Cash Flow	$22.8B	↑ 29.5%
Investing Cash Flow	$-2.3B	↓ 93.76%
Financing Cash Flow	$-19.0B	↑ 65.54%

	FY22	Y/Y Change
Operating Cash Flow	$24.9B	↑ 9.51%
Investing Cash Flow	$-623.0M	↓ 73.42%
Financing Cash Flow	$-24.8B	↑ 30.27%

	FY23	Y/Y Change
Operating Cash Flow	$22.8B	↓ 8.44%
Investing Cash Flow	$-2.0B	↑ 222.47%
Financing Cash Flow	$-17.2B	↓ 30.56%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$6.3B	↑ 50.7%
Investing Cash Flow	$-341.0M	↓ 31.66%
Financing Cash Flow	$-3.9B	↓ 36.69%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$7.6B	↑ 19.86%
Investing Cash Flow	$-369.0M	↑ 8.21%
Financing Cash Flow	$-2.7B	↓ 32.12%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$4.8B	↓ 37.25%
Investing Cash Flow	$-800.0M	↑ 116.8%
Financing Cash Flow	$-4.4B	↑ 67.19%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$4.0B	↓ 15.0%
Investing Cash Flow	$-9.6B	↑ 1098.5%
Financing Cash Flow	$10.8B	↓ 343.18%

Abbvie Technicals Summary

Sell

Neutral

Buy

Abbvie is currently in a neutral trading position according to technical analysis indicators.

Abbvie Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Abbvie Inc	-0.77%	1.64%	13.56%	31.93%	95.41%
Eli Lilly And Company	2.64%	-13.75%	34.54%	181.13%	485.58%
Johnson & Johnson	-6.9%	-3.12%	-7.47%	-14.13%	-1.0%
Merck & Co. Inc.	-1.14%	-26.26%	-8.9%	29.47%	7.23%
Novo Nordisk A/s	-19.09%	-40.26%	-17.22%	56.78%	193.26%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Abbvie Inc	59.97	59.97	0.41	10.94	0.56	0.08	0.04	3.41
Eli Lilly And Company	81.9	81.9	0.71	13.15	0.65	0.14	0.01	15.83
Johnson & Johnson	23.73	23.73	0.86	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.82	20.82	0.07	7.74	0.28	0.11	0.03	17.58
Novo Nordisk A/s	34.71	34.71	1.54	22.85	0.89	0.21	0.01	27.07

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Abbvie Inc	Buy	$303.1B	95.41%	59.97	9.22%
Eli Lilly And Company	Buy	$681.3B	485.58%	81.9	20.48%
Johnson & Johnson	Buy	$345.7B	-1.0%	23.73	16.74%
Merck & Co. Inc.	Buy	$251.7B	7.23%	20.82	19.23%
Novo Nordisk A/s	Buy	$482.1B	193.26%	34.71	35.01%

Abbvie Dividend announcements

Abbvie Dividends March, 2025
In the quarter ending March,2025. Abbvie has declared dividend of $1.64
Read More

About Abbvie

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Organization	Abbvie
Employees	50000
CEO	Mr. Richard A. Gonzalez
Industry	Health Technology

Management People of Abbvie

Name	Title
Mr. Richard A. Gonzalez	Executive Chairman
Mr. Robert A. Michael	CEO & Director
Mr. Scott T. Reents	Executive VP & CFO
Dr. Azita Saleki-Gerhardt Ph.D.	Executive VP & COO
Mr. Jeffrey Ryan Stewart	Executive VP & Chief Commercial Officer
Dr. Roopal Thakkar M.D.	Executive VP of Research and Development & Chief Scientific Officer
Ms. Elizabeth Shea	Senior Vice President of Investor Relations
Mr. Perry C. Siatis	Executive VP, General Counsel & Secretary
Mr. Sanjay Narayan	Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Timothy J. Richmond	Executive VP & Chief Human Resources Officer

Important FAQs about investing in Abbvie from India :

What is Abbvie share price today?

Abbvie share price today stands at $175.58, Open: $171.79 ; Previous Close: $171.52 ; High: $176.75 ; Low: $171.58 ; 52 Week High: $207.32 ; 52 Week Low: $153.09. The stock opens at $171.79, after a previous close of $171.52. The stock reached a daily high of $176.75 and a low of $171.58, with a 52-week high of $207.32 and a 52-week low of $153.09.

Can Indians buy Abbvie shares?

Yes, Indians can invest in the Abbvie (ABBV) from India.

With INDmoney, you can buy Abbvie at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Abbvie at zero transaction cost.

How can I buy Abbvie shares from India?

It is very easy to buy Abbvie from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Abbvie be purchased?

Yes, you can buy fractional shares of Abbvie with INDmoney app.

What are the documents required to start investing in Abbvie stocks?

To start investing in Abbvie, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.